Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 36567 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. Any 

member of the public may submit written 

comments no later than 15 days after the 

meeting. 

Information is also available on the 

Institute’s/Center’s home page: https://

www.nccih.nih.gov/news/events/advisorycouncil-78th-meeting, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.213, Research and Training 

in Complementary and Alternative Medicine, 

National Institutes of Health, HHS) 

Dated: July 7, 2021. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14739 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: High ASS1 Expressing 

Tumors Embody a Purine Rich 

Genomic Signature and Sensitivity to 

Purine Depletion 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute 

(NCI), an institute of the National 

Institutes of Health, Department of 

Health and Human Services, is 

contemplating the grant of an exclusive, 

sublicensable patent license to Yeda 

Research & Development Co, Ltd 

(‘‘YEDA’’), the technology transfer 

company of the Weizmann Institute of 

Science, a non-profit research 

institution located in Rehovot, Israel for 

NCI’s rights to the patent applications 

listed in the Supplementary Information 

section of this notice. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before July 27, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

exclusive patent license should be 

directed to: Kevin W. Chang, Ph.D., 

Senior Licensing and Patenting Manager 

at Telephone: (240)–276–6910 or at 

Email: changke@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

The following and all continuing U.S. 

and foreign patents/patent applications 

thereof are the intellectual properties to 

be licensed under the prospective 

agreement to YEDA: PCT Patent 

Application PCT/IL2020/050708, filed 

June 24, 2020 and entitled ‘‘High ASS1 

Expressing Tumors Embody A Purine 

Rich Genomic Signature And Sensitivity 

To Purine Depletion’’ [HHS Reference 

No. E–210–2020–0–PCT–01]. 

The patent rights in these inventions 

have been assigned to the Government 

of the United States of America and 

YEDA. The prospective license will be 

for the purpose of consolidating the 

patent rights to YEDA, one of the coowners of said rights, for commercial 

development and marketing. 

Consolidation of these co-owned rights 

is intended to expedite development of 

the invention, consistent with the goals 

of the Bayh-Dole Act codified as 35 

U.S.C. 200–212. 

The prospective patent license will be 

worldwide, exclusive, and may be 

limited to those fields of use 

commensurate in scope with the patent 

rights. It will be sublicensable, and any 

sublicenses granted by YEDA will be 

subject to the provisions of 37 CFR parts 

401 and 404. 

This technology discloses methods of 

treating a high argininosuccinate 

synthase (ASS1) expressing solid tumor 

with a combination of a purine synthase 

inhibitor or an agent that increases the 

pyrimidine to purine ratio in a cell, and 

an immune-modulating drug, such as a 

checkpoint inhibitor. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

include terms for the sharing of royalty 

income with NCI from commercial 

sublicenses of the patent rights. The 

prospective exclusive license may be 

granted unless within fifteen (15) days 

from the date of this published notice, 

the National Cancer Institute receives 

written evidence and argument that 

establishes that the grant of the license 

would not be consistent with the 

requirements of 35 U.S.C. 209 and 37 

CFR part 404. 

Complete applications for a license 

that are timely filed in response to this 

notice will be treated as objections to 

the grant of the contemplated exclusive 

patent license. In response to this 

Notice, the public may file comments or 

objections. Comments and objections, 

other than those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: July 6, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–14681 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Notice To Announce Request for 

Information (RFI) Inviting Input on the 

ICCFASD 2022–2026 Strategic Plan 

Outline 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The Interagency Coordinating 

Committee on Fetal Alcohol Spectrum 

Disorders (ICCFASD) is developing an 

updated strategic plan to guide its 

efforts over the next five years. As 

sponsor and chair of the ICCFASD, the 

National Institute on Alcohol Abuse and 

Alcoholism (NIAAA) will be issuing a 

Request for Information to seek 

comments on the draft outline of the 

ICCFASD’s 2022–2026 Strategic Plan 

from diverse stakeholders, including 

scientific experts, health care providers, 

patients and family members, advocacy 

groups, other federal agencies, and nongovernmental scientific, professional, 

and healthcare organizations. 

DATES: Comments must be received by 

August 31, 2021, to ensure 

consideration. Responses will be 

reviewed by ICCFASD members and 

considered during the development of 

the 2022–2026 Strategic Plan. 

ADDRESSES: To view and comment on 

the strategic plan outline, please visit 

our online response form: RFI online 

response form. 

FOR FURTHER INFORMATION CONTACT: 

Tatiana Balachova, ICCFASD Executive 

Secretary, National Institute on Alcohol 

Abuse and Alcoholism, NIH, 6700B 

Rockledge Drive, Bethesda, MD 20817. 

Phone: 301–443–5726, Email: NIAAAICCFASD@mail.nih.gov. 

SUPPLEMENTARY INFORMATION: In 

accordance with the 21st Century Cures 

Act, NIH institutes are required to 


khammond on DSKJM1Z7X2PROD with NOTICES